TSVT250117C2500
- 0.05
- -0.05-50.00%
2seventy bio Newsroom
2seventy Bio: Buy Rating Amidst Challenges and Growth Potential in BCMA CAR-T Therapy
2seventy Bio (TSVT) Gets a Hold From Morgan Stanley
Goldman Sachs Maintains 2seventy Bio(TSVT.US) With Sell Rating, Maintains Target Price $2
TD Cowen Maintains 2seventy Bio(TSVT.US) With Hold Rating
TD Cowen Reaffirms Their Hold Rating on 2seventy Bio (TSVT)
Analysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), 2seventy Bio (TSVT)
TD Cowen Maintains 2seventy Bio(TSVT.US) With Hold Rating
Leerink Partners Maintains 2seventy Bio(TSVT.US) With Buy Rating, Announces Target Price $15
Buy Rating Affirmed for 2seventy Bio Despite Trial Setback: Niche Market Strategy and Safety Profile Underpin Positive Outlook
Morgan Stanley Maintains 2seventy Bio(TSVT.US) With Hold Rating, Maintains Target Price $6
Hold Rating on 2seventy Bio Amidst Strategic Shifts and Enrollment Challenges
Analysts' Opinions Are Mixed on These Healthcare Stocks: Walgreens Boots Alliance (WBA), 2seventy Bio (TSVT) and Repare Therapeutics (RPTX)
Morgan Stanley Maintains 2seventy Bio(TSVT.US) With Hold Rating, Maintains Target Price $6
Analysts Offer Insights on Healthcare Companies: 2seventy Bio (TSVT), Illumina (ILMN) and Larimar Therapeutics (LRMR)
Leerink Partners Keeps Their Buy Rating on 2seventy Bio (TSVT)
Hold Rating on 2seventy Bio: Balancing Modest Sales Growth Against Competitive Market Pressures
2seventy Bio Price Target Cut to $6.00/Share From $7.00 by Morgan Stanley
2seventy Bio Analyst Ratings
Morgan Stanley Maintains Equal-Weight on 2seventy Bio, Lowers Price Target to $6
Morgan Stanley Maintains 2seventy Bio(TSVT.US) With Hold Rating, Cuts Target Price to $6